Comparison of the effect of standard and novel immunosuppressive drugs on CMV-specific T-cell cytokine profiling

Transplantation

Volumn 95, Issue 3, 2013, Pages 448-455

  Egli, Adrian ^a   Kumar, Deepali ^a   Broscheit, Chris ^b   O'Shea, Daire ^a   Humar, Atul ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

Author keywords

Belatacept; Costimulation; JAK3 Inhibitor; Mycophenolate; Sirolimus; Tacrolimus; Tofacitinib; Transplantation

Indexed keywords

BELATACEPT; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RANTES; RAPAMYCIN; TACROLIMUS; TOFACITINIB; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOKINE RESPONSE; CYTOMEGALOVIRUS; DONOR; DOSE RESPONSE; DRUG POTENCY; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TH1 CELL; TH2 CELL;

ADULT; CYTOKINES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; MYCOPHENOLIC ACID; PIPERIDINES; PYRIMIDINES; PYRROLES; SIROLIMUS; T-LYMPHOCYTES; TACROLIMUS; TH1 CELLS; TH2 CELLS; TRANSCRIPTOME;

EID: 84873409207     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318276a19f     Document Type: Article

References (32)

1. Humar A, Snydman D. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009; 9: S78.
2. Crough T, Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev 2009; 22: 76.
3. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715.
4. Palladino G, Scherle PA, Gerhard W. Activity of CD4+ T-cell clones of type 1 and type 2 in generation of influenza virus-specific cytotoxic responses in vitro. J Virol 1991; 65: 6071.
5. De Carli M, D'Elios MM, Zancuoghi G, et al. Human Th1 and Th2 cells: functional properties, regulation of development and role in autoimmunity. Autoimmunity 1994; 18: 301.
6. Ferber IA, Lee HJ, Zonin F, et al. GATA-3 significantly downregulates IFN-gamma production from developing Th1 cells in addition to inducing IL-4 and IL-5 levels. Clin Immunol 1999; 91: 134.
7. Egli A, Binggeli S, Bodaghi S, et al. Cytomegalovirus and polyomavirus BK posttransplant. Nephrol Dial Transplant 2007; 22: viii72.
8. Egli A, Kohli S, Dickenmann M, et al. Inhibition of polyomavirus BK-specific T-cell responses by immunosuppressive drugs. Transplantation 2009; 88: 1161.
9. Sester U, Gartner BC, Wilkens H, et al. Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation. Am J Transplant 2005; 5: 1483.
10. Vincenti F, Dritselis A, Kirkpatrick P. Belatacept. Nat Rev Drug Discov 2011; 10: 655.
11. Latek R, Fleener C, Lamian V, et al. Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation. Transplantation 2009; 87: 926.
12. Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008; 26: 127.
13. Vijayakrishnan L, Venkataramanan R, Gulati P. Treating inflammation with the Janus kinase inhibitor CP-690,550. Trends Pharmacol Sci 2011; 32: 25.
14. Bunde T, Kirchner A, Hoffmeister B, et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 2005; 201: 1031.
15. Egli A, Binet I, Binggeli S, et al. Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients. J Transl Med 2008; 6: 29.
16. La Rosa C, Limaye AP, Krishnan A, et al. Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease. J Infect Dis 2007; 195: 633.
17. Lilleri D, Zelini P, Fornara C, et al. Inconsistent responses of cytomegalovirus-specific T cells to pp65 and IE-1 versus infected dendritic cells in organ transplant recipients. Am J Transplant 2007; 7: 1997.
18. Sester M, Sester U, Gartner B, et al. Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation 2001; 71: 1287.
19. Asberg A, Jardine AG, Bignamini AA, et al. Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients. Am J Transplant 2010; 10: 1881.
20. Lacey SF, La Rosa C, Zhou W, et al. Functional comparison of T cells recognizing cytomegalovirus pp65 and intermediate-early antigen polypeptides in hematopoietic stem-cell transplant and solid organ transplant recipients. J Infect Dis 2006; 194: 1410.
21. Nordoy I, Muller F, Nordal KP, et al. Chemokines and soluble adhesion molecules in renal transplant recipients with cytomegalovirus infection. Clin Exp Immunol 2000; 120: 333.
22. Sadeghi M, Daniel V, Naujokat C, et al. Dysregulated cytokine responses during cytomegalovirus infection in renal transplant recipients. Transplantation 2008; 86: 275.
23. Essa S, Pacsa A, Raghupathy R, et al. Low levels of Th1-type cytokines and increased levels of Th2-type cytokines in kidney transplant recipients with active cytomegalovirus infection. Transplant Proc 2009; 41: 1643.
24. Essa S, Raghupathy R, Pacsa AS, et al. Th1-type cytokines production is decreased in kidney transplant recipients with active cytomegalovirus infection. J Med Virol 2000; 60: 223.
25. Villacres MC, Longmate J, Auge C, et al. Predominant type 1 CMVspecific memory T-helper response in humans: evidence for gender differences in cytokine secretion. Hum Immunol 2004; 65: 476.
26. van de Berg PJ, Heutinck KM, Raabe R, et al. Human cytomegalovirus induces systemic immune activation characterized by a type 1 cytokine signature. J Infect Dis 2010; 202: 690.
27. Song A, Nikolcheva T, Krensky AM. Transcriptional regulation of RANTES expression in T lymphocytes. Immunol Rev 2000; 177: 236.
28. Moller A, Iwasaki K, Kawamura A, et al. The disposition of 14Clabeled tacrolimus after intravenous and oral administration in healthy human subjects. Drug Metab Dispos 1999; 27: 633.
29. Napoli KL, Wang ME, Stepkowski SM, et al. Distribution of sirolimus in rat tissue. Clin Biochem 1997; 30: 135.
30. Clippinger AJ, Maguire TG, Alwine JC. The changing role of mTOR kinase in the maintenance of protein synthesis during human cytomegalovirus infection. J Virol 2011; 85: 3930.
31. Brennan DC, Legendre C, Patel D, et al. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials. Am J Transplant 2011; 11: 2453.
32. Hahn JN, Falck VG, Jirik FR. Smad4 deficiency in T cells leads to the Th17-associated development of premalignant gastroduodenal lesions in mice. J Clin Invest 2011; 121: 4030.